(SLDB) Solid Biosciences - Overview
Stock: SGT-003, SGT-212, SGT-501, SGT-601, SGT-401
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 76.5% |
| Relative Tail Risk | -12.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.18 |
| Alpha | 92.87 |
| Character TTM | |
|---|---|
| Beta | 1.516 |
| Beta Downside | 1.478 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.92% |
| CAGR/Max DD | -0.03 |
Description: SLDB Solid Biosciences December 29, 2025
Solid Biosciences (NASDAQ:SLDB) is a U.S.-based biotech that builds gene-therapy platforms for neuromuscular and cardiac disorders. Its lead candidate, SGT-003, is in a combined Phase 1/2 trial for Duchenne muscular dystrophy (DMD), while a pipeline of early-stage programs targets Friedreich’s ataxia (SGT-212, Phase 1b), catecholaminergic polymorphic ventricular tachycardia (SGT-501, preclinical), and several rare dilated cardiomyopathies (SGT-601, SGT-401, SGT-701). The firm also develops proprietary capsid libraries, regulatory elements (promoters, UTRs, introns), immunomodulation tools, and dual-gene expression technology.
As of the most recent 10-Q (Q2 2024), Solid reported approximately $150 million in cash and marketable securities, giving it an estimated 12-month runway at current burn (~$12-$14 million per quarter). The DMD market is projected to exceed $5 billion by 2028, driven by a growing patient pool and premium pricing for disease-modifying gene therapies, which positions SGT-003 as a potentially high-value asset if it achieves functional improvement benchmarks comparable to competing AAV-based candidates.
Sector-wide, biotech capital inflows remain robust, with U.S. gene-therapy funding up ~22 % YoY in 2023, and the FDA’s “Regenerative Medicine Advanced Therapy” (RMAT) designation accelerating review timelines for promising candidates. Solid’s collaboration with Ultragenyx and multiple university licenses diversify risk but also tie milestone revenue to the success of its preclinical programs, which are inherently high-variance.
For a deeper, data-driven look at how Solid’s valuation compares to sector benchmarks, you may find the analytical tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -167.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA -5.31 > 1.0 |
| NWC/Revenue: 6674 % < 20% (prev 3307 %; Δ 3367 % < -1%) |
| CFO/TA -0.48 > 3% & CFO -132.4m > Net Income -167.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (94.4m) vs 12m ago 127.8% < -2% |
| Gross Margin: 46.96% > 18% (prev 0.46%; Δ 4650 % > 0.5%) |
| Asset Turnover: 1.29% > 50% (prev 2.24%; Δ -0.95% > 0%) |
| Interest Coverage Ratio: -309.7 > 6 (EBITDA TTM -165.3m / Interest Expense TTM 539.0k) |
Altman Z'' -15.00
| A: 0.76 (Total Current Assets 244.9m - Total Current Liabilities 36.3m) / Total Assets 273.9m |
| B: -3.31 (Retained Earnings -908.0m / Total Assets 273.9m) |
| C: -0.69 (EBIT TTM -166.9m / Avg Total Assets 242.9m) |
| D: -16.22 (Book Value of Equity -907.9m / Total Liabilities 56.0m) |
| Altman-Z'' Score: -27.46 = D |
What is the price of SLDB shares?
Over the past week, the price has changed by +0.93%, over one month by +18.76%, over three months by +54.69% and over the past year by +108.31%.
Is SLDB a buy, sell or hold?
- StrongBuy: 7
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SLDB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.8 | 141.6% |
| Analysts Target Price | 15.8 | 141.6% |
| ValueRay Target Price | 7.5 | 15.6% |
SLDB Fundamental Data Overview February 05, 2026
P/B = 2.2985
Revenue TTM = 3.12m USD
EBIT TTM = -166.9m USD
EBITDA TTM = -165.3m USD
Long Term Debt = 21.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.31m USD (from shortTermDebt, last quarter)
Debt = 21.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -39.4m USD (from netDebt column, last quarter)
Enterprise Value = 295.3m USD (509.5m + Debt 21.9m - CCE 236.1m)
Interest Coverage Ratio = -309.7 (Ebit TTM -166.9m / Interest Expense TTM 539.0k)
EV/FCF = -2.22x (Enterprise Value 295.3m / FCF TTM -133.2m)
FCF Yield = -45.09% (FCF TTM -133.2m / Enterprise Value 295.3m)
FCF Margin = -4263 % (FCF TTM -133.2m / Revenue TTM 3.12m)
Net Margin = -5350 % (Net Income TTM -167.1m / Revenue TTM 3.12m)
Gross Margin = 46.96% ((Revenue TTM 3.12m - Cost of Revenue TTM 1.66m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.08 (Enterprise Value 295.3m / Total Assets 273.9m)
Interest Expense / Debt = 1.53% (Interest Expense 336.0k / Debt 21.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -131.9m (EBIT -166.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.74 (Total Current Assets 244.9m / Total Current Liabilities 36.3m)
Debt / Equity = 0.10 (Debt 21.9m / totalStockholderEquity, last quarter 217.9m)
Debt / EBITDA = 0.24 (negative EBITDA) (Net Debt -39.4m / EBITDA -165.3m)
Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -39.4m / FCF TTM -133.2m)
Total Stockholder Equity = 227.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -68.82% (Net Income -167.1m / Total Assets 273.9m)
RoE = -73.63% (Net Income TTM -167.1m / Total Stockholder Equity 227.0m)
RoCE = -67.06% (EBIT -166.9m / Capital Employed (Equity 227.0m + L.T.Debt 21.9m))
RoIC = -58.10% (negative operating profit) (NOPAT -131.9m / Invested Capital 227.0m)
WACC = 11.08% (E(509.5m)/V(531.5m) * Re(11.50%) + D(21.9m)/V(531.5m) * Rd(1.53%) * (1-Tc(0.21)))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 80.38%
Fair Price DCF = unknown (Cash Flow -133.2m)
EPS Correlation: 85.37 | EPS CAGR: 33.08% | SUE: 1.59 | # QB: 2
Revenue Correlation: -47.58 | Revenue CAGR: -34.53% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.51 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=10
EPS next Year (2026-12-31): EPS=-2.01 | Chg30d=+0.000 | Revisions Net=-3 | Growth EPS=+4.6% | Growth Revenue=+0.0%